Large pooled analysis reveals no safety concerns with PCSK9-inhibitor
Jennifer Robinson (University of Iowa, Iowa City, IA, USA)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
ISA2015 | Clinical Breakthroughs In a pooled analysis of 14 trials with PCSK9-inhibitor alirocumab, in over 5000 patients who achieved LDL <25 of <15 mg/dL, followed for up to 2 years, no safety signals were observed.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: